The historic rise of Viagra has long been a example of pharmaceutical success, but its future within the broader sector now raises questions about long-term yields . Copycat versions are eroding exclusivity , leading to worries that supporting companies closely tied to Viagra's once-dominant influence could be a speculative move , especially given